Fabiola Cecchi, PharmD, PhD
Affiliations: | 2007-2012 | Urologic Oncology Branch | National Cancer Institue-NIH |
2013- | Astra-Zeneca (R&D) |
Google:
"Fabiola Cecchi"Mean distance: (not calculated yet)
Children
Sign in to add traineeJoseph Reilly | research assistant | 2009-2011 | National Cancer Institute |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Cecchi F, Rex K, Schmidt J, et al. (2023) Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Cancers. 15 |
Shah MA, Wainberg ZA, Catenacci DVT, et al. (2022) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 17: e0276211 |
Shah MA, Wainberg ZA, Catenacci DVT, et al. (2021) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. Plos One. 16: e0261994 |
Kummar S, Srivastava AK, Navas T, et al. (2021) Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. Investigational New Drugs |
Di Bartolomeo M, Raimondi A, Cecchi F, et al. (2020) Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori. 300891620930803 |
Solocinski K, Padget MR, Fabian KP, et al. (2020) Overcoming hypoxia-induced functional suppression of NK cells. Journal For Immunotherapy of Cancer. 8 |
Schaff LR, Yan D, Thyparambil S, et al. (2019) Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Journal of Neuro-Oncology |
Serna G, Ruiz-Pace F, Cecchi F, et al. (2019) Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports. 9: 13568 |
Toulmonde M, Pulido M, Ray-Coquard I, et al. (2019) Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. The Lancet. Oncology |
Novoplansky O, Fury M, Prasad M, et al. (2019) MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International Journal of Cancer |